Travere Therapeutics, Inc. (TVTX) Q3 2025 10-Q Quarterly Report
Travere Therapeutics, Inc. (TVTX) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Oct 30, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
Travere Therapeutics, Inc. Q3 2025 10-Q Analysis
Risk Factors
- • New commercialization risk: FDA full approval of FILSPARI in Sept 2024 replacing prior accelerated approval in Feb 2023 requires expanded U.S. sales force training and market adoption efforts
- • Most material update: Expanded risks on third-party commercialization outside U.S. due to CSL Vifor acquisition by CSL Limited and possible reduced marketing support
- • Regulatory risk: $6.2M invoice paid in Oct 2024 relating to French authority price recalculation on Kolbam sales 2015-2020, appeal ongoing with uncertain final liability
- • Operational risk: Dependence on third-party sole-source manufacturers and distributors risks supply disruptions and increased cost from tariff or trade policy changes
- • Financial risk: Exposure to pricing pressure from U.S. MFN drug pricing executive order (May 2025) and ongoing healthcare payer reimbursement restrictions affecting product demand and pricing
Travere Therapeutics, Inc. Q3 2025 Quarterly FinancialsXBRL
Revenue
$165M
▲ +162.1% YoY▲ +44.0% QoQ
Net Income
$26M
▲ +146.9% YoY▲ +301.5% QoQ
Operating Margin
15.1%
▲ +10439bp YoY▲ +2618bp QoQ
Net Margin
15.6%
▲ +10274bp YoY▲ +2674bp QoQ
ROE
34.9%
Total Assets
$539M
EPS (Diluted)
$0.29
▲ +141.4% YoY▲ +307.1% QoQ
Operating Cash Flow
$14M
▲ +133.7% YoY▲ +187.3% QoQ
Source: XBRL data from Travere Therapeutics, Inc. Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.
Get deeper insights on Travere Therapeutics, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.